
USD
+$0.00
(+0.00%
)At Close (As of Oct 24, 2025)
$529.61M
Market Cap
-
P/E Ratio
-3.53
EPS
$12.34
52 Week High
$2.23
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $37K |
| Total Revenue | $37K |
| Cost Of Revenue | $6.7M |
| Costof Goods And Services Sold | $6.7M |
| Operating Income | -$188M |
| Selling General And Administrative | $47M |
| Research And Development | $141M |
| Operating Expenses | $188M |
| Investment Income Net | - |
| Net Interest Income | $27M |
| Interest Income | $27M |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $6.7M |
| Income Before Tax | -$161M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$161M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$195M |
| Ebitda | -$188M |
| Net Income | -$161M |
| Field | Value (USD) |
|---|---|
| Total Assets | $560M |
| Total Current Assets | $435M |
| Cash And Cash Equivalents At Carrying Value | $149M |
| Cash And Short Term Investments | $149M |
| Inventory | - |
| Current Net Receivables | - |
| Total Non Current Assets | $125M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | $81M |
| Short Term Investments | $276M |
| Other Current Assets | $10M |
| Other Non Current Assets | - |
| Total Liabilities | $50M |
| Total Current Liabilities | $29M |
| Current Accounts Payable | $4.4M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $5.6M |
| Total Non Current Liabilities | $21M |
| Capital Lease Obligations | $25M |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $25M |
| Other Current Liabilities | $19M |
| Other Non Current Liabilities | $193K |
| Total Shareholder Equity | $511M |
| Treasury Stock | - |
| Retained Earnings | -$576M |
| Common Stock | $5K |
| Common Stock Shares Outstanding | $54M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$135M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $6.7M |
| Capital Expenditures | $3.8M |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | -$302M |
| Cashflow From Financing | $337M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$161M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $37K |
| Total Revenue | $37K |
| Cost Of Revenue | $6.7M |
| Costof Goods And Services Sold | $6.7M |
| Operating Income | -$188M |
| Selling General And Administrative | $47M |
| Research And Development | $141M |
| Operating Expenses | $188M |
| Investment Income Net | - |
| Net Interest Income | $27M |
| Interest Income | $27M |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $6.7M |
| Income Before Tax | -$161M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$161M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$195M |
| Ebitda | -$188M |
| Net Income | -$161M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company headquartered in Emeryville, California, dedicated to pioneering advanced therapeutics using its proprietary adeno-associated virus (AAV) vector platform. The company is at the forefront of addressing critical unmet medical needs in ophthalmology, neurology, and rare diseases, with a strong focus on transforming patient outcomes through innovative gene therapies. With a well-developed pipeline and strategic collaborations, 4D Molecular Therapeutics is strategically positioned to lead advancements in the biotherapeutics sector, aiming to bring novel treatments to market and establish itself as a prominent player in the field.